title: [Plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance].
abstract: OBJECTIVE
  To study the plasma levels of interleukin6 (IL-6 ) and interleukin10 (IL-10) in patients with lymphoma and their association with the clinical characteristics and prognosis.
  
  
  METHODS
  The plasma levels of IL-6 and IL-10 were measured in 132 lymphoma patients and 132 healthy controls using enzyme-linked immunosorbent assay (ELISA).
  
  
  RESULTS
  The levels of plasma IL-6 and IL-10 in lymphoma patients were significantly higher than those in healthy controls (P<0.05). The plasm a levels of IL-6 were significant higher in T non-Hodgkins lymphoma (T-NHL) patients than in B non-Hodgkins lymphoma (B-NHL) patients (P<0.05), and were similar between other groups of different subtypes of lymphoma (P>0.05). Patients of Kazak nationality had a significantly higher plasma IL-6 level than those of Han and Uygur nationalities (P<0.05). The presence of B symptoms, a high risk defined by the International Prognostic Index (IPI), high levels of plasma β(2)-MG, and elevated LDH and C-reactive protein (CRP) levels were all associated with a significantly increased plasma IL-6 level (P<0.05), and patients with Ann Arbor stage III-IV disease, B symptoms, and high plasma β(2)-MG and CRP levels had significantly higher IL-10 levels (P<0.05). The plasma IL-6 and IL-10 levels were significantly lower in patients with complete remission than in those with partial remission and progressive disease and than in those without treatment (P<0.05). Plasma IL-10 was positively correlated to IL-6 and β(2)-MG levels (P<0.05).
  
  
  CONCLUSIONS
  Lymphoma patients have significantly increased plasma IL-6 and IL-10 levels with correlation to the tumor load. Plasma levels of IL-6 and IL-10 may serve as useful indicators for predicting the response to therapy and prognosis of lymphoma.
authors.affiliation: Department of Pathologys, Xinjiang Medical University, Urumqi 830054, China. wx780@163.com
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Hua-rong
authors.initials: HR
authors.lastname: Zhao
authors.forename: Xia
authors.initials: X
authors.lastname: Gu
authors.forename: Pan
authors.initials: P
authors.lastname: Liu
authors.forename: Hadeti
authors.initials: H
authors.lastname: Bikmituofu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002648:Child; D005260:Female; D006689:Hodgkin Disease / Q000097:blood; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008223:Lymphoma / Q000097:blood* / Q000145:classification; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000145:classification; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D047368:Tumor Burden; D055815:Young Adult
chemical_list: D015850:Interleukin-6; D016753:Interleukin-10